Photobiomodulation Therapy Ameliorates Glutamatergic Dysfunction in Mice with Chronic Unpredictable Mild Stress-Induced Depression

Figure 3

Effects of PBMT on dendritic atrophy and expression of GluA1 in the cortex and hippocampus of depressed mice. (a) Typical staining of MAP2 (green) in the cortex and hippocampal regions from CUMS mice with or without PBMT and the control group. Nuclei were counterstained with DAPI (blue). Scale bar, 100 μm ( per group). (b) Representative immunofluorescent image analysis of NeuN-positive cells (red) in the hippocampal and cortex regions of each group; scale bar represents 100 μm. (c) Quantification of MAP2 density in the hippocampal and cortex regions of different groups. (d) Quantitative analyses of the NeuN-positive cells in the hippocampal and cortex regions of different groups. (e) Western blot and quantification analysis of MAP2 from control vs. chronic stressed mice without or with PBMT treatment (-8 per group). (f) Western blot and quantification analysis of GluA1 from control vs. chronic stressed mice without or with PBMT treatment. (g) Representative western blot and quantification analysis of S845 in chronic stressed mice under the treatment with or without PBMT. (h) Western blot and quantification analysis of PSD95 from control vs. chronic stressed mice without or with PBMT treatment. All the data represent . , , and , one-way ANOVA with Tukey’s post hoc analysis. MAP2: microtubule-associated protein 2; PSD95: postsynaptic density 95.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)